脾内转染白细胞介素-2和/或12基因增强接种肝癌大鼠T细胞功能研究

目的　探讨脾内直接注射白细胞介素IL 2、12基因对血IL 2和IL 12 ,以及T细胞活性的影响。方法　构建IL 2和或IL 12基因的逆转录病毒载体。含IL 2和或IL 12基因的包装细胞于不同时间进行脾内注射转染脾细胞。比较大鼠血IL 2和IL 12浓度、T细胞活性和毒性反应。结果　IL单基因治疗后血清IL 2或IL 12明显增高。IL 2 /IL 12联合基因组中血清IL 2和IL 12增加较单基因组显著。病理示肝癌组织中淋巴细胞浸润明显增多。IL治疗组治疗后 7d ,T细胞活性较对照组显著增高 (P <0 .0 5 )。联合基因组治疗后 7d ,T细胞功能较IL单基因组增强(P <0 .0 5 )。结论　脾内直接注射IL 2和或IL 12基因可增强T细胞活性 ,IL联合基因治疗优于IL单基因。     

白细胞介素-4和γ-干扰素基因联合治疗胶质瘤

目的 探讨逆转录病毒载体介导的白细胞介素(IL)-4和γ-干扰素(IFN)基因联合治疗胶质瘤的作用。方法构建携带IL-4或IFN-γ基因的逆转录病毒载体，将其导入逆转录病毒包装细胞；将携带IL-4和IFN-γ基因的逆转录病毒包装细胞分别或联合注射到脑内荷瘤大鼠的肿瘤组织中，观察其治疗作用。结果成功获得携带治疗基因的逆转录病毒包装细胞PA317IFN-γ和PA317IL-4，所产病毒滴度分别为2x10^6cfu／ml和2．5x10^6cfu／ml。包装细胞瘤内注射能够诱导大鼠产生抗肿瘤免疫反应，杀伤肿瘤细胞，联合应用具有协同治疗作用。结论携带IL-4或IFN-γ基因的逆转录病毒包装细胞瘤内注射是一种有效的胶质瘤基因治疗方法，两者联合应用具有协同治疗作用。     

白细胞介素12融合基因联合白细胞介素2对肝癌的基因治疗

我们在肝癌基因治疗目的基因筛选的实验中发现,在大鼠肝癌模型中,IL-12的基因治疗作用最为显著[1,2],若同时联合IL-2,有望进一步提高对肝癌的治疗效果. 1.材料与方法:大鼠肝癌细胞株CBRH3由中科院细胞所谢弘教授惠赠.以质粒GCp35Ep40PN为模板,PCR分别扩增p35和p40亚基基因.以PCR产物为模板,用p40上游引物和p35下游引物再次进行PCR反应,构建mIL-12融合基因.mIL-12和hIL-2基因分别插入逆转录病毒载体GCXEXPN,命名为GCIL12EXPN和GCXEIL2PN、GCIL12E-IL2PN.按常规方法筛选逆转录病毒载体GCIL12EXPN、GCXEIL2PN、GCIL12E-IL2PN的PA317包装细胞株,测病毒滴度.用CBRH3建立大鼠接种肝癌模型,分为生理盐水、LacZ载体对照组和IL-2、IL-12、IL-12+IL-2治疗组,每组10只大鼠,将包装细胞株脾内注射进行治疗.方差分析结果.     

重组人IL-1Ra与TGF-β1联合基因体外转染兔膝关节软骨细胞的研究

背景:多基因联合转染具有增强功能基因协同效应、消除短板差异等作用,因而目前被受到广泛重视。目的:观察以逆转录病毒(RV)为载体,介导白介素-1受体拮抗蛋白(IL-1Ra)基因单独转染及其与转化生长因子-β1(TGF-β1)基因共同转染兔膝软骨细胞后的表达,及对其增殖代谢的影响。方法:构建逆转录病毒载体PLNCX2-IL-1Ra-GFP 与 PLNCX2-TGF-β1-RFP,将其转染至包装细胞 PT67,待形成阳性克隆后扩增培养,收集病毒上清,并计算病毒上清滴度。将体外培养的软骨细胞分为空白转染组、PLNCX2空载体转染组、IL-1Ra单基因转染组及IL-1Ra +TGF-β1双基因转染组。酶联免疫吸附分析法(ELISA)进行瞬时基因表达(细胞转染后48 h)及稳定基因表达(筛选后4周)的检测;免疫组织化学染色法检测各组IL-1Ra、TGF-β1及Ⅱ型胶原的表达;流式细胞仪检测各组细胞生长周期比例。结果:PLNCX2-IL-1Ra-GFP 与 PLNCX2-TGF-β1-RFP 转染包装细胞后分别有绿色荧光与红色荧光表达;空白组与PLNCX2空载体转染组的上述指标无统计学差异(P>0.05);ELISA检测示基因转染组有明显基因表达;与空白组及PLNCX2空载体转染组相比,双基因转染组IL-1Ra、TGF-β1、Ⅱ型胶原含量明显提高,IL-1Ra基因转染组IL-1Ra含量提高明显,但TGF-β1、Ⅱ型胶原含量提高不明显;双基因转染组软骨细胞位于S期的比例明显增高,与其他组比较有统计学差异(P<0.05)。结论:逆转录病毒载体构建成功,基因转染软骨细胞后可获得稳定表达,双基因转染的软骨细胞生物学活性优于单基因转染,为基因治疗骨关节炎(OA)的研究提供实验基础。     

白细胞介素12对肝癌基因治疗的实验研究

目的 研究携带白细胞介素１２（ＩＬ－１２）基因逆转录病毒载体对体内肝癌生长抑制作用,探索基因治疗肝癌新途径。方法 构建携带ＩＬ－１２的逆转录病毒载体,转染逆转录病毒包装细胞系ＰＡ３１７,应用该包装细胞对实验性肝癌大鼠进行治疗,观察抗肿瘤作用,免疫功能变化。     

脾动脉注射IL-2在大鼠肝癌模型中的定位及其对免疫功能的影响

目的：研究不同途径注射IL－2后在大鼠肝癌模型体内的分布和存留情况及其对机体免疫功能的影响。方法 建立大鼠原位肝癌模型，分别经腹腔（IP组），阴茎静脉（IV组），脾动脉（SA组）注射以Iodogen法标记的^131I-IL-2,比较其在各组中的分布存留情况；并测定内源性IL－2水平，NK和LAK细胞活性，T细胞亚群改变以及sIL-2R,TGF-β，IL-10水平。结果：与腹腔及静脉注射途径相比，脾动脉注射组的^131I-IL-2血药浓度及肝脏，脾脏内的放射性浓聚升高更为迅速，药物高峰维持时间也显著延长。IP和IV组在给药后第4天，IL－2水平达高峰，以后逐渐下降，至第8天接近对照组水平，SA组IL－2峰值出现在第6天，至第8天尚呈较高水平。各组sIL-2R,TGF-β，IL－10水平均较对照组为低，其中SA组降低维持时间最长。IP和IV组的NK和LAK细胞活性，CD4^ 亚群，CD4^ /CD8^ 虽有增加，但与对照组相比无统计学显著，而在SA组中上述各指标相对均有显著提升（P＜0．05）。结论：经脾动脉应用IL－2，能迅速升高血液，肝脏及脾脏内IL－2浓度，并在较长时间内维持较高浓度。经脾动脉应用免疫治疗对荷瘤大鼠免疫状态的改善显著优于经腹腔和静脉给药，有望成为免疫治疗的新途径。     

白细胞介素12基因治疗结肠癌的实验研究

目的观察携白细胞介素12(mIL-12)基因逆转录病毒载体的包装细胞(PA317-mIL-12)瘤内注射后,对肿瘤生长的抑制及对荷瘤动物生存的影响。方法在非免疫缺陷的结肠癌动物模型上分别施以化疗、放射免疫(放免)导向治疗、PA317-mIL-12基因治疗以及放免导向与IL-12基因联合治疗,比较各治疗组的肿瘤抑制效果和荷瘤动物的生存情况。结果经筛选后的携有mIL-12逆转录病毒载体包装细胞系PA317-mIL-12的上清,mIL-12浓度48h达27ng/106细胞。治疗3周后,IL-12基因治疗组(GT组)和IL-12基因与RIT联合治疗组(GT加RIT组)无论瘤体积还是瘤重量均明显低于对照组,生存率明显高于对照组(P<0.01)。结论PA317-mIL-12瘤内注射可有效抑制肿瘤生长,延长荷瘤动物的生存时间。基因治疗疗效优于化疗、放免导向治疗。放免导向与IL-12基因联合治疗疗效更佳。     

转Fas配体基因的树突状细胞在诱导大鼠肝移植免疫耐受中的作用

目的 探讨受者体内注射转FasL基因垢树突状细胞（DC）诱导大鼠肝移植免疫耐受的作用机制。方法 建立SD大鼠→Wistar大鼠肝移植模型。分别于术前5d给受者腹腔注射转染多药耐药基因（mdr1)的DC细胞或转染FasL基因的DC细胞,并设空白对照组和环孢素A（CsA)对照组。术后3d和7d测定移植肝功能,册时以半定量逆转录聚合酶链反应（RT-PCR）检测移植肝组织中Fas,Fas配体（FasL)及白细胞介素12（IL-12）,并观察受鼠的存活时间。结果 空白对照组的大鼠术后9-15d全部死亡,CsA治疗组及转FasL基因治疗组;空白对照组及转mdr1基因治疗组的FasL及IL-12表达增高,而CsA治疗组及转FasL基因治疗组的FasL及IL-12呈不表达或低表达。结论 转染FasL基因的DC细胞能有效地诱导大鼠肝移植免疫耐受,其机理可能与诱导了肝脏内浸润淋巴细胞凋亡及抑制IL-2的表达有关。     

白细胞介素18对肝细胞肝癌治疗的实验研究

目的研究携带白介素 18基因的腺病毒载体包装细胞对体内肝癌生长抑制作用。方法　构建白介素 18腺病毒载体 ,并进一步通过与Ad5腺病毒DNA TPC复合物同源重组 ,制备IL 18的复制缺陷性重组腺病毒 ,并对实验性肝癌大鼠进行治疗 ,观察抗癌作用。结果IL 18的复制缺陷性重组腺病毒包装细胞肝内局部或脾内注射后抑制肝癌细胞系CBRH3 的生长 ,接种CBRH3 第 1,3天注射者长期生存 ,第 5 ,7天注射者生存期延长空白组及空载体对照组注射者均见癌灶生长 [P =0 0 0 15 ,生存时间 (2 1± 4 )d]。结论肝癌局部及脾内注射IL 18的复制缺陷性重组腺病毒包装细胞能产生有效的抗癌作用 ,早期治疗优于晚期治疗 ,脾内注射安全有效。     

乌司他丁对脓毒症急性肾损伤大鼠肾脏NOD1受体和血IL-18水平的影响

目的 探讨乌司他丁对腹主动脉阻断联合腹腔注射脂多糖内毒素（LPS）构建严重脓毒症大鼠肾脏NOD1受体表达和血IL-18水平的影响.方法 48只Wistar大鼠随机分为假手术组（SHAM组）、腹主动脉阻断联合腹腔注射LPS组（AAC＋ LPS组）、腹主动脉阻断联合腹腔注射LPS乌司他丁干预组（AAC＋ LPS＋U组）、腹主动脉阻断腹腔LPS生理盐水对照组（AAC＋ LPS＋ NS组）.大鼠于术后或干预后8h处死,收集血和大鼠肾脏,检测血中Cr、BUN水平,ELISA方法检测血中IL-18浓度,免疫组化方法检测肾脏NOD1蛋白的表达,RT-PCR方法检测肾脏NOD1 mRNA的表达.结果 NOD1受体mRNA和蛋白的表达,血中IL-18和Cr、BUN水平在AAC ＋LPS组和AAC＋LPS ＋NS组最强,AAC＋ LPS＋U组较前两组下降,差异有统计学意义（P＜0.05）.结论 乌司他丁可能通过抑制肾脏NOD1受体的表达,抑制血中IL-18的分泌从而在脓毒症时发挥抗炎和肾脏保护作用.     

两种不同方式介导IL-12真核表达载体抑制肝移植瘤生长的研究

目的:比较两种不同方式介导IL-12真核表达载体抑制肝移植瘤生长的效果.方法:利用鼠肝癌细胞系H22建立肝移植瘤模型,以脂质体介导IL-12质粒腹腔注射或直接瘤内注射给荷瘤鼠,每周1次,共2次.治疗后每周两次测量瘤体大小,取血利用ELISA法检测血清中IL-12及IL-2的含量变化;MTT法检测NK细胞杀伤活性.结果:直接瘤内注射组瘤体积明显小于腹腔注射组(P＜0.05),直接瘤内注射组血清IL-12、IL-2浓度有明显的周期变化,但二者NK细胞杀伤率无明显差异.结论:脂质体介导直接瘤内注射IL-12真核表达载体可有效抑制肝移植瘤的生长.     

Antitumor effect of simultaneous transfer of interleukin-12 and interleukin-18 genes and its mechanism in a mouse bladder cancer model

BACKGROUND: The objectives of this study were to evaluate the antitumor effects of the simultaneous introduction of interleukin 12 (IL-12) and IL-18 genes into a mouse bladder cancer cell line (MBT2). We intended to compare these with those of either gene alone and to investigate the mechanism of the effects induced by the transfer of IL-12 and/or IL-18 genes in this model system. METHODS: We transfected the IL-12 and/or IL-18 genes into MBT2 cells by the liposome-mediated gene transfer method. We confirmed the secretion of IL-12 and/or IL-18 by enzyme-linked immunosorbent assay. Parental (MBT2/P), IL-12-transfected (MBT2/IL-12), IL-18-transfected (MBT2/IL-18) or both IL-12- and IL-18-transfected (MBT2/Both) cells were subcutaneously or intravenously injected into syngeneic C3H mice. To analyze the mechanism of tumor rejection, these clones were subcutaneously injected into naive nude mice and those depleted with natural killer (NK) cells by antibody. RESULTS: MBT2/IL-12, MBT2/IL-18 and MBT2/Both were completely rejected when they were injected subcutaneously or intravenously into syngeneic mice. However, MBT2/IL-12, but not MBT2/IL-18, could grow in nude mice. Moreover, the antitumor effect of MBT2/IL-18 was partially abrogated when injected into nude mice of which NK cells were depleted by antibody treatment. MBT2/Both was completely rejected in both nude mice with and without NK cells. CONCLUSION: The results of the present study indicate that T cells and NK cells seem to play important roles in the antitumor effects by the secretion of IL-12 and IL-18, respectively, and MBT2/Both possesses both mechanisms.     

IL-12 cDNA direct injection: antimetastatic effect from a single injection in a murine hepatic metastases model

BACKGROUND: Interleukin 12 (IL-12) gene therapy is an effective antitumor agent in local and metastatic murine tumor models. We sought to evaluate the antimetastatic effect of IL-12 cDNA in a liver metastases model. MATERIALS AND METHODS: A liver metastases model was induced by creating a "primary" splenic tumor through inoculation of 1 x 10(5) TS/A adenocarcinoma cells directly into the inferior pole of the spleen in female BALB/c mice. On day 4, 50 microg of IL-12 cDNA or control plasmid DNA was injected into splenic tumor, followed by splenectomy on day 8. Mice were sacrificed on day 25 to assess liver tumor burden. IL-12 mRNA and mIL-12 and IFN-gamma protein levels were assessed after IL-12 injection. Peripheral blood CD4+, CD8+, and NK cells were quantified on day 14 using FACS. To determine the significance of site of cytokine DNA injection, IL-12 cDNA was injected on day 4 into splenic tumor or into the non-involved spleen after isolation of the inferior and superior portions of the spleen, respectively, with surgical clips. Splenectomy was performed on day 8 and sacrifice was performed on day 25. RESULTS: IL-12 mRNA was detected in the liver 8 h after injection, with a peak at 24 h. After splenic injection, protein levels of IL-12 and IFN-gamma were detectable in the liver and spleen 24 h after treatment. IL-12 and IFN-gamma were not detectable in control animals. In the peripheral blood, there was a marked increase in NK cells (13% of total lymphocytes versus 4%, control) and in the CD4+/CD8+ ratio (5.5 versus 1.9). At day 25, there was a marked antimetastatic effect after IL-12 injection into either splenic tumor [liver:body weight, 6.2 versus 10.9 (control), P = 0.007] or non-involved spleen (6.8 g versus 10.7 g, P = 0.005). There was no difference in the antimetastatic effect between animals injected into splenic tumor or non-involved spleen (P = 0.3). CONCLUSION: Injection with a single dose of IL-12 cDNA into splenic tumor or non-involved spleen resulted in a profound antimetastatic effect. Splenic IL-12 injection results in mRNA expression in the liver, protein expression in the liver and spleen, and a marked increase in NK cells and the CD4+/CD8+ ratio in peripheral blood.     

转染大鼠白细胞介素10基因的骨髓源性肝干细胞移植治疗大鼠肝纤维化

目的 探讨转染大鼠白细胞介素10(IL-10)基因的β2m-/Thy-1+骨髓源性肝干细胞(BDLSC)移植对大鼠肝纤维化的治疗效果.方法 分选Wistar大鼠的β3m-/Thy-1+BDLSC,转染大鼠IL-10基因.Wistar大鼠皮下注射CCl4,制作肝纤维化模型,分为3组:(1)模型组,经大鼠门静脉分支输注无菌生理盐水1 ml;(2)BDSC组,经大鼠门静脉分支输注β2m-/Thy-1+BDLSC悬液1ml(含2×105个细胞);(3)IL-10组,经大鼠门静脉分支输注转染1L-10基因的β2m-/Thy-1+BDLSC悬液1 ml(含2×105个细胞);另以皮下注射橄榄油的Wistar大鼠为对照(正常组).用细胞核染色剂二脒基苯基吲哚(DAPI)标记β2m-/Thy-1+BDLSC,以观察该细胞在肝内的定位情况.观察各组大鼠肝组织病理学改变和胶原的沉积情况,检测其肝功能和凝血功能.结果 大鼠肝组织中可见DAPI标记的β2m-/Thy-1+BDLSC.模型组大鼠的肝组织病理学改变明显,BDLSC组病理学改变有所减轻,IL-10组的组织形态最接近正常组.模型组大鼠肝组织内胶原沉积明显增多,BDLSC组胶原沉积较少,IL-10组胶原沉积明显减少.IL-10组大鼠的血清丙氨酸转氨酶(ALT)、天冬氨酸转氨酶(AST)、碱性磷酸酶(ALP)和胆红素总量(TBIL)以及全血凝血酶原时间(PT)和活化部分凝血激酶时间(APTT)均低于模型组,差异均有统计学意义(P<0.05),其中ALT、TBIL、PT和APTT均降至正常组水平,与BDLSC组相比较,差异有统计学意义(P<0.05).结论 转染大鼠IL-10基因的β2m-/Thy-1+BDLSC移植对大鼠肝纤维化有一定的治疗效果.     

Electroporation-mediated transfer of plasmid DNA encoding IL-10 attenuates orthotopic tracheal allograft stenosis in rats

BACKGROUND: Electroporation has been shown to increase the efficacy of intramuscular injection of plasmid DNA, resulting in a higher level of foreign gene expression. Using this technique, we examined the effect of viral IL-10 gene transfer on the prevention of tracheal allograft stenosis in an animal model. METHODS: On the day of tracheal transplantation, recipient Lewis rats were intramuscularly injected with either plasmid pCAGGS-LacZ or plasmid pCAGGS-viral IL-10, followed immediately by electroporation. Tracheas from Brown Norway donors were transplanted into the backs of Lewis recipients, and the histology of the grafts were assessed 2 and 4 weeks after transplantation. RESULTS: The serum level of IL-10 peaked at 2000 pg/ml one day after injection; the level then slowly decreased, but was maintained above 1000 pg/ml until 8 days after injection. At Day 28, the airway lumina of the tracheal allografts were almost completely obliterated by fibroproliferative tissue in the control pCAGGS-LacZ-treated rats. In rats injected once with pCAGGS-viral IL-10, luminal obliteration was significantly decreased compared with the control pCAGGS-LacZ-treated rats (mean luminal opening 46.8% vs 0% p<0.05). The loss of epithelial cells lining the airway was also decreased in the IL-10-treated group (mean epithelial coverage 42% vs 5% p<0.05). Multiple injections with pCAGGS-viral IL-10 did not further improve the histological changes. CONCLUSION: IL-10 gene transfer by intramuscular injection using electroporation attenuated tracheal allograft stenosis associated with mild epithelial injury.     

肿瘤浸润性淋巴细胞在白细胞介素-2、-4协同下局部过继免疫治疗膀胱癌的实验研究

目的　观察膀胱癌肿瘤浸润性淋巴细胞 (TIL)联合不同细胞因子瘤灶内过继免疫抗癌的效应及对机体全身抗肿瘤免疫机制的影响。方法　建立BTT73 9动物模型 ,分离、培养TIL。采用正交设计实验方法 ,将TIL、白细胞介素 (IL) 2、 4及三因素交互组合悬液分别直接注射至瘤体内 ,定期测量肿瘤体积 ,免疫治疗 2周后检测NK细胞活性、T淋巴细胞转刺激指数 ,观察组织学及超微结构变化。结果　比较对照组 ,治疗 2周时各TIL相关组均不同程度抑制了膀胱肿瘤体积的增长 ,且NK细胞活性及T淋巴细胞转化增殖能力得以提高 (P <0 .0 5 )。TIL/IL 2疗法明显抑制了瘤体的增长 ,免疫治疗 1周后即表现出协同增强效应 (P <0 .0 5 ) ,而NK细胞活性及T淋巴细胞转刺激指数也显著提高 (P <0 .0 5 )。TIL/IL 2 /IL 4组获得了较强的抗癌功效 ,但与TIL/IL 2组差异无显著性 (P >0 .0 5 )。超微结构变化显示出TIL强烈的溶癌现象。结论　TIL在细胞因子特别是IL 2协同下瘤灶内注射的局部免疫疗法 ,具有较强的抗膀胱癌效应 ,并显著提高了机体全身抗瘤免疫功能。     

Antitumor effect to IL-12 administration into the portal vein on murine liver metastasis

Background/Purpose: Interleukin (IL)-12 has been shown to possess potent antitumor activity, and an antitumor effect of systemic IL-12 administration has been reported in liver metastasis models. Methods: In this study, we examined the usefulness of local IL-12 administration into the portal system in the treatment of liver metastasis. First, we confirmed the antitumor effect of recombinant IL-12 (rIL-12) on MC-38 tumors in an intracutaneous model. In the murine liver metastasis model, 1 × 10⁵ of MC-38 cells were injected into the portal vein on day 0, and the spleen was transpositioned subcutaneously for administration of rIL-12 continually into the portal system. From days 3 to 7, 0.1 μg rIL-12 was administered intraperitoneally or intrasplenicly, while Hanks' Balanced Salf Solution (HBSS) was injected intrasplenicly in the control group. Results: The liver weight in the rIL-12 intraperitoneal treatment group (1.88 ± 0.37 g) and that in the rIL-12 intrasplenic treatment group (1.43 ± 0.21 g) were significantly less than that in the HBSS group (2.86 ± 0.74 g; P < 0.05). The numbers of metastatic nodules in the rIL-12 intraperitoneal treatment group (22.3 ± 17.1) and in the rIL-12 intrasplenic treatment group (12.4 ± 13.8) were significantly less than that in the HBSS group (137.1 ± 44.9; P < 0.05). Complete regression of the tumor was observed in one of six mice in the rIL-12 intrasplenic treatment group. This antitumor effect of rIL-12 on MC-38 liver metastasis was not observed in interferon (IFN)-γ knockout mice. Intraportal administration of IL-12-transduced fibroblasts, which were syngeneic to C57BL/6 mice, had an antitumor effect in the MC-38 liver metastasis model. Conclusions: These results suggested that the local administration of IL-12 into the portal system would be a useful strategy for the treatment of liver metastasis. Received: April 4, 2002 / Accepted: July 1, 2002 Acknowledgment. The authors are grateful to Dr. H. Okamura (Hyogo Medical College, Japan), for kindly providing recombinant mIL-12, and Ms. Reiko Tsubouchi for her excellent technical assistance. Offprint requests to: T. Kitagawa     

IL-17A对脂多糖致老年大鼠早期中枢炎症和场景性恐惧实验的作用

目的探讨IL-17A对脂多糖(LPS)致老年大鼠早期中枢炎症和恐惧实验的影响。方法雄性SD大鼠70只,18月龄,首先取30只大鼠随机均分为五组:腹腔注射生理盐水(生理盐水组,A组)、腹腔注射LPS 500μg/kg 6h组(B组)、12h组(C组)、24h组(D组)、48h组(E组)。检测LPS注射后各组大鼠海马IL-17A的表达。随后,将剩余40只大鼠随机均分为四组:空白对照组(O组)、IL-17A抗体组(P组)、LPS腹腔注射组(Q组)、IL-17A抗体+LPS腹腔注射组(R组)。P组和R组大鼠侧脑室给予IL-17A抗体3μl(200μg/μl),O组和Q组给予同体积生理盐水;30min后,Q组和R组大鼠腹腔注射LPS(500μg/kg),O组和P组给予同体积生理盐水,24h后各组行场景性恐惧实验,记录四组大鼠的僵直时间,检测海马TNF-α和IL-6水平及CA1区Iba1阳性细胞的表达。结果 B、C和D组大鼠海马中IL-17A的表达明显高于A组(P0.01),E与A组IL-17A的表达差异无统计学意义;Q组和R组大鼠僵直反应时间明显短于O组(P0.05或P0.01),R组大鼠僵直反应时间明显长于Q组(P0.01);Q组和R组大鼠海马TNF-α和IL-6的水平明显高于O组(P0.01),R组大鼠海马TNF-α和IL-6水平明显低于Q组(P0.01);Q组和R组大鼠海马CA1区Iba1阳性细胞数目明显多于O组,R组大鼠海马CA1区Iba1阳性细胞数目明显少于Q组(P0.05)。结论 IL-17A参与LPS引起的老年大鼠早期中枢炎症因子TNF-α和IL-6的表达、小胶质细胞的活化以及场景性恐惧实验的僵直时间改变。